186 related articles for article (PubMed ID: 18337118)
1. ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells.
Declèves X; Bihorel S; Debray M; Yousif S; Camenisch G; Scherrmann JM
Pharmacol Res; 2008 Mar; 57(3):214-22. PubMed ID: 18337118
[TBL] [Abstract][Full Text] [Related]
2. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.
Bihorel S; Camenisch G; Lemaire M; Scherrmann JM
J Neurochem; 2007 Sep; 102(6):1749-1757. PubMed ID: 17696988
[TBL] [Abstract][Full Text] [Related]
3. The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate.
Oostendorp RL; Marchetti S; Beijnen JH; Mazzanti R; Schellens JH
Cancer Chemother Pharmacol; 2007 May; 59(6):855-60. PubMed ID: 17180388
[TBL] [Abstract][Full Text] [Related]
4. Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar.
Bihorel S; Camenisch G; Lemaire M; Scherrmann JM
Pharm Res; 2007 Sep; 24(9):1720-8. PubMed ID: 17380257
[TBL] [Abstract][Full Text] [Related]
5. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.
Breedveld P; Pluim D; Cipriani G; Wielinga P; van Tellingen O; Schinkel AH; Schellens JH
Cancer Res; 2005 Apr; 65(7):2577-82. PubMed ID: 15805252
[TBL] [Abstract][Full Text] [Related]
6. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice.
Zhou L; Schmidt K; Nelson FR; Zelesky V; Troutman MD; Feng B
Drug Metab Dispos; 2009 May; 37(5):946-55. PubMed ID: 19225039
[TBL] [Abstract][Full Text] [Related]
7. Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2.
Shukla S; Sauna ZE; Ambudkar SV
Leukemia; 2008 Feb; 22(2):445-7. PubMed ID: 17690695
[No Abstract] [Full Text] [Related]
8. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia.
Wang L; Giannoudis A; Lane S; Williamson P; Pirmohamed M; Clark RE
Clin Pharmacol Ther; 2008 Feb; 83(2):258-64. PubMed ID: 17568400
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.
Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M
Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006
[TBL] [Abstract][Full Text] [Related]
10. Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells.
Hirayama C; Watanabe H; Nakashima R; Nanbu T; Hamada A; Kuniyasu A; Nakayama H; Kawaguchi T; Saito H
Pharm Res; 2008 Apr; 25(4):827-35. PubMed ID: 17934801
[TBL] [Abstract][Full Text] [Related]
11. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
[TBL] [Abstract][Full Text] [Related]
12. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
Graber-Maier A; Gutmann H; Drewe J
Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
[TBL] [Abstract][Full Text] [Related]
13. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
[TBL] [Abstract][Full Text] [Related]
14. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps.
Burger H; van Tol H; Brok M; Wiemer EA; de Bruijn EA; Guetens G; de Boeck G; Sparreboom A; Verweij J; Nooter K
Cancer Biol Ther; 2005 Jul; 4(7):747-52. PubMed ID: 15970668
[TBL] [Abstract][Full Text] [Related]
15. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979.
Shepard RL; Cao J; Starling JJ; Dantzig AH
Int J Cancer; 2003 Jan; 103(1):121-5. PubMed ID: 12455064
[TBL] [Abstract][Full Text] [Related]
16. Closing the gaps: a full scan of the intestinal expression of p-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in male and female rats.
MacLean C; Moenning U; Reichel A; Fricker G
Drug Metab Dispos; 2008 Jul; 36(7):1249-54. PubMed ID: 18378562
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.
Burger H; van Tol H; Boersma AW; Brok M; Wiemer EA; Stoter G; Nooter K
Blood; 2004 Nov; 104(9):2940-2. PubMed ID: 15251980
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
Chen Y; Agarwal S; Shaik NM; Chen C; Yang Z; Elmquist WF
J Pharmacol Exp Ther; 2009 Sep; 330(3):956-63. PubMed ID: 19491323
[TBL] [Abstract][Full Text] [Related]
19. Influence of chemosensitizers on resistance mechanisms in daunorubicin-resistant Ehrlich ascites tumour cells.
Nielsen D; Eriksen J; Maare C; Friche E; Skovsgaard T
Cancer Chemother Pharmacol; 2002 Jun; 49(6):453-60. PubMed ID: 12107549
[TBL] [Abstract][Full Text] [Related]
20. Involvement of the multidrug resistance protein 3 in drug sensitivity and its expression in human glioma.
Haga S; Hinoshita E; Ikezaki K; Fukui M; Scheffer GL; Uchiumi T; Kuwano M
Jpn J Cancer Res; 2001 Feb; 92(2):211-9. PubMed ID: 11223551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
